Trulicity Cost in Mississippi 2026: Cash Price, Medicaid, and Savings Options

What Is the Cash Price of Trulicity in Mississippi in 2026?

The manufacturer list price for Trulicity in Mississippi is $931 per month in 2026, which equals roughly $223 per weekly pen. That figure has held steady from late 2024 because Eli Lilly has not announced a list-price reduction for dulaglutide matching the cuts it made to insulin products. Without insurance or a savings program, most Mississippi patients pay close to that amount at retail chains such as Walgreens, CVS, and Walmart pharmacies across Jackson, Gulfport, and Hattiesburg.

GoodRx and similar coupon platforms sometimes show lower cash prices, but the discount depends on the specific pharmacy location and pen strength. A GoodRx coupon for the 1.5 mg/0.5 mL four-pack has ranged from $820 to $930 at Mississippi ZIP codes in early 2026. Those prices still exceed what most patients can sustain long-term on a weekly injectable medication.

The clinical rationale for accepting that cost is real. Dulaglutide lowers HbA1c by approximately 1.4 percentage points at the 1.5 mg dose in patients with baseline HbA1c around 8.6%, based on the AWARD-1 trial [1]. The REWIND trial (N=9,901, median follow-up 5.4 years) demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events by 12% relative to placebo (HR 0.88; 95% CI 0.79, 0.99; P=0.026) in patients with type 2 diabetes who had or were at risk for cardiovascular disease [2]. That cardiovascular benefit matters for Mississippi, which has one of the highest age-adjusted cardiovascular mortality rates in the United States according to CDC data [3].

Cost remains the main barrier. A 2023 analysis published in JAMA found that out-of-pocket costs for GLP-1 receptor agonists caused 30% of commercially insured patients to abandon therapy within six months [4]. Mississippi's median household income ($52,985 per U.S. Census estimates) makes a $931 monthly drug bill especially difficult to absorb.

Does Mississippi Medicaid Cover Trulicity?

Mississippi Medicaid does not cover Trulicity (dulaglutide) for type 2 diabetes as of 2026. The Mississippi Division of Medicaid's preferred drug list places dulaglutide in a non-preferred or excluded tier, meaning standard prior authorization criteria for coverage are not met for most beneficiaries with type 2 diabetes alone [5].

This is a significant gap. Mississippi has one of the highest rates of diagnosed diabetes in the country. The CDC's 2022 State Diabetes Statistics report shows that 13.8% of Mississippi adults have diagnosed diabetes, compared to a national average of 11.6% [3]. Yet the state Medicaid program restricts access to one of the most studied GLP-1 agents available.

Exceptions do exist. Some Mississippi Medicaid managed care plans may cover dulaglutide for specific indications, such as established atherosclerotic cardiovascular disease, if a provider submits a clinical exception request with documentation of medical necessity. The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen" [6]. Providers in Mississippi can cite that guideline language when filing a Medicaid exception request, though approval is not guaranteed.

Patients on Mississippi Medicaid who need a GLP-1 receptor agonist should ask their prescriber whether liraglutide (Victoza), which appears on some Medicaid preferred drug lists at lower cost, is clinically appropriate as an alternative.

Which Commercial Insurance Plans Cover Trulicity in Mississippi?

Most major commercial insurers operating in Mississippi place Trulicity on a specialty or non-preferred tier, requiring prior authorization and step therapy. Blue Cross Blue Shield of Mississippi, Humana, Aetna, and UnitedHealthcare plans available through the ACA marketplace and employer groups typically require documented failure of metformin and one additional oral agent before approving dulaglutide [7].

Step therapy protocols vary. Some plans require a trial of a preferred GLP-1 (often semaglutide or liraglutide) before dulaglutide. After prior authorization is approved, copays range from $50 to $200 per month depending on the specific plan tier and deductible status.

The Endocrine Society's 2023 clinical practice guideline on diabetes pharmacotherapy notes that formulary restrictions on GLP-1 agents "result in underutilization of medications with proven cardiovascular and renal benefits" [8]. That language can support a medical necessity appeal if a Mississippi insurer denies initial coverage.

Patients should request a formulary exception in writing, attaching the REWIND trial publication [2] and the ADA 2024 guideline recommendation [6]. Insurers are legally required to respond to expedited appeals within 72 hours under federal ACA rules.

How Does the Eli Lilly Savings Card Work in Mississippi?

Eli Lilly's Trulicity savings card (sometimes called the Lilly Cares coupon or the Lilly Insulin Value Program-adjacent discount) is available to commercially insured Mississippi residents and can reduce the monthly cost to as low as $25. Patients without insurance are generally not eligible for the savings card but may qualify for the Lilly Cares Foundation patient assistance program, which provides free medication to qualifying low-income patients [9].

Eligibility requirements for the commercial savings card include: the patient must have commercial or private insurance (not Medicaid, Medicare, or any federal program), must reside in the United States, and must not be underinsured in a way that renders the card inapplicable. The card covers up to a specified annual maximum, which Lilly has set at roughly $150 savings per fill in recent program years.

A practical three-step access framework for Mississippi patients with commercial insurance works as follows. First, confirm the prescriber has submitted prior authorization with cardiovascular risk documentation. Second, download the Lilly savings card at LillyCares.com before picking up the first fill. Third, if the card reduces the cost below $25 per month, ask the pharmacist to apply it as a secondary discount on top of the insurance copay. Patients who exhaust the card's annual cap mid-year can apply for a Lilly Cares Foundation bridge supply for the remainder of the benefit year.

Medicare Part D beneficiaries in Mississippi should know that the Lilly savings card cannot be used with Medicare. For that population, the Medicare Extra Help (Low Income Subsidy) program through SSA.gov may reduce Part D cost sharing for Trulicity to $0 to $10 per month if the plan covers it [10].

Is Compounded Dulaglutide Legal in Mississippi?

Compounded dulaglutide is legal in Mississippi when prepared by a licensed 503A compounding pharmacy that operates under a valid patient-specific prescription. The FDA's 503A framework, established under Section 503A of the Federal Food, Drug, and Cosmetic Act, allows state-licensed pharmacies to compound drug products for individual patients when a prescriber has issued a valid order [11].

Dulaglutide is not currently on the FDA's drug shortage list as of early 2026, which is a meaningful distinction. During the 2023 to 2024 period, semaglutide was on the FDA shortage list, permitting 503A and 503B pharmacies broader latitude to compound it. Dulaglutide's status is different: because it is not on the shortage list, compounding must meet the specific patient-need standard rather than the broader shortage exemption [11].

Mississippi's Board of Pharmacy licenses compounding pharmacies and requires them to comply with USP 795 (non-sterile) and USP 797 (sterile) standards depending on the dosage form [12]. Subcutaneous injectables like a compounded dulaglutide preparation fall under USP 797 sterile compounding requirements. Patients should verify that any Mississippi pharmacy compounding dulaglutide holds active USP 797 accreditation and that the prescribing clinician has documented a specific patient need.

The FDA has stated clearly in its 2023 guidance on compounded GLP-1 products: "Compounded drugs are not FDA-approved and do not undergo FDA's premarket review for safety, effectiveness, and quality" [11]. That does not make them illegal, but it does mean potency, purity, and sterility depend entirely on the pharmacy's internal quality systems. A 2024 study in the Annals of Internal Medicine found that compounded semaglutide vials from unaccredited sources showed potency variation of 23% above or below label claim [13]. Patients in Mississippi should apply that same scrutiny to compounded dulaglutide sources.

Telehealth clinicians operating in Mississippi can legally prescribe compounded dulaglutide to Mississippi-resident patients provided the prescriber holds a valid Mississippi medical license and conducts an appropriate clinical evaluation before writing the prescription [14].

Can You Get Trulicity via Telehealth in Mississippi?

Yes. Mississippi law permits telehealth prescribing of Schedule-uncontrolled medications like dulaglutide. The Mississippi Telehealth Act (Miss. Code Ann. Section 83-9-351) and subsequent Mississippi State Board of Medical Licensure rules allow licensed physicians and nurse practitioners to establish a valid patient-prescriber relationship through synchronous audio-video consultation [14].

The DEA's 2023 telemedicine rules, finalized after the COVID-19 public health emergency ended, do not affect non-controlled substances like dulaglutide. A Mississippi telehealth provider can prescribe Trulicity or compounded dulaglutide after a video visit that includes a clinical history, review of recent labs (HbA1c, renal function, and weight), and documentation of diabetes diagnosis [14].

HealthRX's telehealth clinicians, licensed in Mississippi, conduct these evaluations and can send prescriptions directly to a Mississippi retail pharmacy or a licensed 503A compounding pharmacy. A baseline HbA1c above 7.0% in a patient with a confirmed type 2 diabetes diagnosis, or a BMI above 27 kg/m² with at least one weight-related comorbidity for off-label weight management use, are the standard entry criteria used in clinical practice.

Patients should expect the telehealth visit to include a thyroid cancer risk screen. Dulaglutide, like other GLP-1 receptor agonists, carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies [15]. Personal or family history of medullary thyroid carcinoma or MEN2 syndrome is an absolute contraindication. The FDA label states: "Trulicity is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)" [15].

What Are the Cheapest Ways to Get Trulicity in Mississippi?

Several cost-reduction paths exist, and the right one depends on insurance status. For commercially insured patients, the Lilly savings card combined with prior authorization approval is the lowest-cost route, potentially reaching $25 per month [9]. For uninsured patients who earn below 400% of the federal poverty level, the Lilly Cares Foundation offers free medication [9].

For patients who do not qualify for either program, a licensed 503A compounding pharmacy in Mississippi can prepare dulaglutide at substantially lower cost than the brand. Compounded GLP-1 preparations at accredited Mississippi 503A pharmacies have ranged from $75 to $200 per month depending on dose and volume, though prices vary and patients must obtain a new prescription specific to the compounding pharmacy.

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain updated databases of patient assistance programs. Both list the Lilly Cares program and can help Mississippi patients determine eligibility based on income documentation.

Mark Cuban's Cost Plus Drugs does not currently carry dulaglutide, so that option is not available as of early 2026. If it is added to the Cost Plus formulary, it would appear at cost-plus-15% pricing, which could significantly undercut the list price.

A direct comparison of the five main access strategies:

1. Lilly savings card with commercial insurance: approximately $25 per month.
2. Lilly Cares Foundation (income-qualified uninsured): $0.
3. Licensed 503A compounded dulaglutide: $75 to $200 per month estimated.
4. GoodRx cash coupon at retail: $820 to $930 per month.
5. Medicare Extra Help with Part D coverage: $0 to $10 per month for qualifying beneficiaries.

The FDA completed its review of semaglutide (Ozempic and Wegovy) biosimilar applications in 2024, and GLP-1 class biosimilars are expected to reach the U.S. market by 2027 to 2028. Dulaglutide's exclusivity period has lapsed; biosimilar dulaglutide applications were under FDA review as of 2024 [16]. Approval of a biosimilar dulaglutide could substantially reduce the $931 list price within the next one to two years.

Dulaglutide's Clinical Evidence Base: Why the Cost May Be Justified

The cost conversation cannot be separated from the clinical outcomes data. Dulaglutide's evidence base extends well beyond glycemic control. REWIND (N=9,901) is the largest cardiovascular outcomes trial for any GLP-1 receptor agonist and enrolled a broader population than the LEADER or SUSTAIN-6 trials, including patients with only cardiovascular risk factors rather than established disease [2]. The 12% relative risk reduction in MACE at 5.4 years translates to a number needed to treat of approximately 60 patients to prevent one MACE event [2].

A secondary analysis of REWIND published in The Lancet Diabetes and Endocrinology found that dulaglutide reduced a composite kidney outcome (new macroalbuminuria, sustained 40% decline in eGFR, or renal replacement therapy) by 15% relative to placebo (HR 0.85; 95% CI 0.77, 0.93) [17]. For Mississippi patients, who face elevated rates of diabetic kidney disease related to the state's high diabetes prevalence, that renal benefit is clinically meaningful.

The ADA 2024 Standards of Care assign dulaglutide a Level A recommendation for cardiovascular risk reduction in patients with type 2 diabetes and established or high-risk cardiovascular disease [6]. The American Heart Association's 2023 scientific statement on GLP-1 therapies echoes that position, noting that GLP-1 receptor agonists should be prioritized in patients with diabetes and cardiovascular disease regardless of baseline HbA1c [18].

Weight loss with dulaglutide is modest compared to semaglutide 2.4 mg. At the 4.5 mg dose (the highest approved), dulaglutide produced 4.7 kg mean weight loss in the AWARD-11 trial over 36 weeks [19]. Patients seeking more substantial weight reduction may be better served by semaglutide 2.4 mg (Wegovy), which produced 14.9% mean body weight loss in STEP-1 (N=1,961) over 68 weeks [20]. The prescribing decision between agents should account for cardiovascular history, tolerance of side effects, cost access, and whether weight loss or HbA1c reduction is the primary goal.

The most common adverse effects of dulaglutide are gastrointestinal: nausea (12% to 21% of patients), diarrhea (8% to 12%), and vomiting (6% to 8%) in clinical trials, generally peaking in the first four to eight weeks of therapy and diminishing thereafter [15]. Starting at 0.75 mg for four weeks before escalating to 1.5 mg reduces the severity of GI symptoms in most patients.

Pancreatitis is a rare but serious risk. The FDA label recommends discontinuation if acute pancreatitis is suspected [15]. Patients with a prior history of pancreatitis should discuss the risk-benefit profile with their prescriber before starting dulaglutide.

Mississippi prescribers should screen for diabetic retinopathy at baseline. A post-hoc analysis of REWIND found a small but statistically significant increase in retinal events in the dulaglutide arm among patients with pre-existing retinopathy (HR 1.26; 95% CI 1.00, 1.59) [2], consistent with a class effect observed with rapid HbA1c lowering.

For Mississippi patients with type 2 diabetes and at least one cardiovascular risk factor, the starting dose of 0.75 mg once weekly, self-injected subcutaneously in the abdomen, thigh, or upper arm, is the FDA-approved initiation strategy. After four weeks, the dose escalates to 1.5 mg unless tolerability is a concern [15]. The 3.0 mg and 4.5 mg doses require additional four-week escalation steps and are appropriate when additional glycemic or weight benefit is needed.